IL17A and AL amyloidosis: Secukinumab, an IL‐17A‐neutralizing antibody, is approved for a variety of inflammatory diseases (Langley et al., 2014) and has shown efficacy for multiple myeloma treatment in a preclinical study (Prabhala et al., 2016).